Why is Hims & Hers stock being hammered today?

Hims & Hers shares fell 14.43% after first-quarter results missed expectations on both revenue and profitability. Revenue rose 3.8% year over year to $608 million, below the $617 million consensus, while adjusted EBITDA dropped 51% to $44.3 million versus $47 million expected. The miss and margin pressure suggest the company will need tighter cost control to meet revised EBITDA guidance.

Analysis

The key read-through is not just a one-quarter miss; it is that HIMS is now in the phase where revenue growth alone is no longer enough to justify the multiple. When adjusted EBITDA falls much faster than sales, the market starts to re-rate the name from a growth compounder to a margin-management story, and those reratings typically compress first, then stabilize only after two clean quarters of expense discipline. That makes the next 4-8 weeks especially fragile because guidance credibility, not demand, becomes the main driver.

The second-order effect is competitive: if HIMS is forced to defend profitability by pulling back on sales and marketing, the beneficiaries are likely to be larger platforms with better unit economics and more durable customer acquisition engines. In telehealth, CAC inflation tends to show up with a lag, so any retrenchment by HIMS could temporarily slow share gains but also signal weaker category economics, which can pressure adjacent consumer-health names. The most important spillover is that investors may start questioning whether branded/compounded mix improvements are enough to offset pharmacy and fulfillment friction, which is a margin ceiling issue rather than a demand issue.

The move may be partly overdone tactically, but not structurally: a 14% drawdown can overshoot if the market is mechanically de-risking into a miss, yet the valuation reset is justified unless management can demonstrate a clear path to 150-250 bps of EBITDA margin recovery over the next two quarters. The contrarian case is that the market could be underestimating the operating leverage if customer retention remains strong and spend is already being trimmed; in that case, the stock can rebound hard on even modest beat-and-raise cadence. But absent that proof, rallies are likely to fade until execution risk is priced lower.

Key Decisions for Investors

• Short HIMS on any post-gap fill attempt over the next 3-10 trading days; target a 2:1 reward/risk into the next earnings guidance update, with invalidation if management shows immediate SG&A cuts and stable cohort retention.
• Buy HIMS put spreads 1-2 months out rather than outright puts; this captures a continued de-rating while limiting theta if the selloff pauses and the stock trades sideways.
• Pair trade: short HIMS / long a higher-quality health-tech or consumer platform with stronger operating leverage over the next quarter; the trade benefits if the market continues rewarding margin durability over revenue growth.
• If long-only exposure is required, wait for evidence of two consecutive quarters of EBITDA margin stabilization before initiating; the asymmetry is better after proof than before, because the main risk is another guidance reset.